CClinicalTrials.gg
RecruitingNCT06786039Updated Aug 5, 2026

Clinical Impact of Non-invasive Neurally Adjusted Ventilatory Assist in Very Preterm Infants

An observational study in Preterm Infant, sponsored by Korea University Anam Hospital. Recruiting at 2 sites in South Korea. Open to participants aged 1 Hour to 48 Hours. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Korea University Anam Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
1 Hour to 48 Hours
Sex
All
01

Study summary

This is a prospective observational study investigating the impact of NIV-NAVA on short-term clinical outcomes and long-term neurodevelopment in very preterm infants.

02

Conditions studied

  • Preterm Infant

Browse trials for

Keywords

  • infant, premature
  • Noninvasive NAVA
03

Who can participate

Ages eligible
1 Hour to 48 Hours
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted to the NICU in Korea University Anam Hospital will be recruited over a 2-year period.

Inclusion criteria

  • Preterm infants born between 27 weeks 0 days to 31 weeks 6 days of gestation
  • Preterm infants who require respiratory support within the first 48 hours of life

Exclusion criteria

Exclusion Criteria:

  • Preterm infants who die within the first 48 hours of life
  • Preterm infants who do not require any respiratory support within the first 48 hours of life.
  • Preterm infants with congenital anomalies affecting the lungs, heart, or other organs that could influence breathing
  • Infants whose parents do not consent to participate in the study
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • NIV-NAVA application

    Preterm infants born between 27 weeks 0 days to 31 weeks 6 days of gestation requiring respiratory support within 48 hours after birth

    Procedure: Non-invasive NAVA

Interventions

  • ProcedureNon-invasive NAVA

    Initiate respiratory assist with NIV-NAVA within 48 hours. The setting of respiratory support will be adjusted based on clinical conditions of each subject. NIV-NAVA could be switched to nasal continuous airway pressure or high flow nasal cannula, and it also could be stopped after initial stabilization. In cases of respiratory distress syndrome, lung surfactant will be administered via the less invasive surfactant administration (LISA) method and avoid endotracheal intubation whenever possible. For who intubated in the delivery room, extubation with NIV-NAVA should be considered as soon as possible. Endotracheal intubation with invasive ventilation could be applied when clinical deteriorations happens.

05

What researchers measure

Primary outcomes

  1. Rate of Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) failure

    NIV-NAVA failure was defined as a participant requiring endotracheal intubation (except brief intubation for only surfactant administration)

    Time frame: through the study completion, during the hospital stay in neonatal intensive care unit up to 3 months

Secondary outcomes

  1. Rate of bronchopulmonary dysplasia (BPD)

    diagnosed according to the Jensen Criteria

    Time frame: at 36 weeks of postmenstrual age

  2. Duration of non-invasive ventilation

    each of NIV-NAVA, nasal continuous positive airway pressure, high flow nasal cannula

    Time frame: through the study completion, during the hospital stay in neonatal intensive care unit up to 3 months

  3. Incidence of periventricular leukomalacia (PVL)

    diagnosed by brain ultrasound or MRI

    Time frame: through the study completion, during the hospital stay in neonatal intensive care unit up to 3 months

  4. Duration of invasive ventilation

    each of high-frequent oscillatory ventilation, conventional mechanical ventilation, NAVA etc

    Time frame: through the study completion, during the hospital stay in neonatal intensive care unit up to 3 months

  5. Incidence of air leaks

    including pneumothorax, pneumomediastinum and pulmonary interstitial emphysema

    Time frame: through the study completion, during the hospital stay in neonatal intensive care unit up to 3 months

  6. Incidence of patent ductus arteriosus (PDA)

    defined by clinical and/or echocardiographic criteria requiring symptomatic treatment (except prophylaxis)

    Time frame: through the study completion, during the hospital stay in neonatal intensive care unit up to 3 months

  7. Time to achieve full enteral feeding

    day of life when milk amount reaches 100 mL/kg/day or higher

    Time frame: through the study completion, during the hospital stay in neonatal intensive care unit up to 3 months

  8. Incidence of intraventricular hemorrhage (IVH)

    defined by the Papile criteria, using cranial ultrasonography (≥grade 2)

    Time frame: through the study completion, during the hospital stay in neonatal intensive care unit up to 3 months

  9. Incidence of retinopathy of prematurity (ROP)

    defined according to the international classification of ROP (≥stage 2)

    Time frame: through the study completion, during the hospital stay in neonatal intensive care unit up to 3 months

  10. Total brain volume (mL)

    Total brain volume (TBV) will be measured from Brain MRI

    Time frame: term equivalent age defined as 37-42 weeks mean postmenstrual age at brain MRI

  11. Intracranial volume (mL)

    Intracranial volume (ICV) will be measured from Brain MRI

    Time frame: term equivalent age defined as 37-42 weeks mean postmenstrual age at brain MRI

  12. Relative sizes of volumes of particular regions of interest

    relative sizes of volumes of particular regions of interest (ROIs) will be measured from brain MRI

    Time frame: term equivalent age defined as 37-42 weeks mean postmenstrual age at brain MRI

  13. Bayley Scales of Infant Development III - 2 yr

    scale scores for each development areas (cognitive, language, motor) score range : 0-200 above average (1-2 SD, score 116-130) average ( 1 to 1 SD, score 85-115) below average (1 to-2 SD, score 84-70) well below average (\<-2 SD, scores \< 70).

    Time frame: 18-24 months of corrected age

  14. Modified Checklist for Autism in Toddlers (M-CHAT)

    autism spectrum disorder screening test result total score 0-2: low risk total score 3-7: moderate risk total score 8-20: high risk

    Time frame: 18-24 months of corrected age

  15. MacArthur-Bates Communication Development Inventory

    language evaluation questionnaire result The criterion for identifying risk for delayed language development was an expressive vocabulary size \<10th percentile

    Time frame: 18-24 months of corrected age

  16. Bayley Scales of Infant Development III - 3 yr

    scale scores for each development areas (cognitive, language, motor) score range : 0-200 above average (1-2 SD, score 116-130) average ( 1 to 1 SD, score 85-115) below average (1 to-2 SD, score 84-70) well below average (\<-2 SD, scores \< 70).

    Time frame: 33-39 months of age

  17. Child Behavior Checklist (CBCL)

    behavior screening questionnaire result t-score ≤ 59: non-clinical symptoms, t-score between 60 and 64: at risk for problem behaviors t-score ≥ 65: clinical symptoms.

    Time frame: 33-39 months of age

06

Study locations

1 of 2 sites recruiting
  • Seoul National Bundang Hospital NICU
    Seongnam-si, Gyeonggi-do 13620, South Korea
    Not yet recruiting
  • Korea University Anam Hospital, NICU
    Seoul, Seoul 02841, South Korea
    • Juyoung Lee, MD, PhD · Contact · juyounglee@korea.ac.kr · +82-2-920-5647
    • Juyoung Lee, MD, PhD · Principal investigator
    • Hannah Cho, MD, PhD · Sub investigator
    Recruiting
07

References and documents

Publications

  • Cho H, Jung YH, Park J, Yang HJ, Kim MJ, Lee J. Feasibility of NIV-NAVA as a primary respiratory support and its clinical impacts in a targeted group of preterm infants: protocol for a prospective observational study. BMJ Open. 2026 Jun 7;16(6):e114353. doi: 10.1136/bmjopen-2025-114353. PubMed 42252137 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT06786039
Lead sponsor
Korea University Anam Hospital
Responsible party
Juyoung Lee (Professor, Korea University Anam Hospital) — Principal investigator
First posted
Jan 22, 2025
Start date
Jan 20, 2025
Primary completion
Dec 20, 2029 (estimated)
Completion
Dec 20, 2030 (estimated)
Last update
Aug 5, 2026

Study contacts

Juyoung Lee, Professor
Contact
juyounglee@korea.ac.kr
+82-2-920-5647
Hannah Cho, Professor
Contact
hannahv2@korea.ac.kr

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion